Loading...
Loading...
TSVT| Name | Value |
|---|---|
| Revenues | 9.0M |
| Cost of Revenue | 5.1M |
| Gross Profit | 3.8M |
| Operating Expense | 24.2M |
| Operating I/L | -20.4M |
| Other Income/Expense | 45.2M |
| Interest Income | 2.5M |
| Pretax | 24.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 24.9M |
2seventy bio, Inc. is a cell and gene therapy company specializing in the research, development, and commercialization of cancer treatments in the United States. The company's product pipeline includes idecabtagene vicleucel, ide-cel or Abecma, and bb21217, which are CAR-T cell product candidates designed for the treatment of multiple myeloma. 2seventy bio, Inc. generates revenue through the sale and licensing of its innovative cell and gene therapy products, as well as through collaboration arrangements with companies like Bristol-Myers Squibb Company.
